Gene Therapy: The Time Is NowDelivering corrective genes into a patient's own diseased cells and disrupting a medical and insurance industry along the way
Curator’s Pick: “Forget the price. What’s the value of that treatment?”
What if we could fix a patient’s own cells and cure their disease once and for all instead of treating a chronic illness over their lifetime? The solution exists but it’s expensive. Nick Leschly, chief bluebird, explains how biotechnology can deliver corrective genes into a patient’s diseased cells and disrupt the medical and insurance industries along the way.
Nick Leschly assumed the role of president and CEO for bluebird bio in September 2010. Formerly a partner of Third Rock Ventures since its founding in 2007, he became the interim president of bluebird bio in March 2010 in conjunction with Third Rock’s investment in the company’s Series B round. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, as well as identifying and evaluating new investments. Nick serves on the board of Edimer Pharmaceuticals and was the former interim chief business officer of Agios Pharmaceuticals. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product and alliance leader for VELCADE™. Nick also founded and served as CEO of MedXtend Corporation. He holds a B.S. in molecular biology from Princeton University and an M.B.A. from Wharton Business School. Nick is the founder and chairman of The CAVU Foundation, a non-profit dedicated to improving the health of underprivileged children.